Medefil
Private Company
Funding information not available
Overview
Medefil is a private, commercial-stage specialty pharmaceutical company with a 25-year history, initially built on manufacturing prefilled flush syringes. It has evolved into a fully integrated developer and manufacturer of generic injectable drugs, leveraging state-of-the-art R&D and manufacturing infrastructure. The company's strategy targets critical and complex injectables with supply shortages or development challenges, aiming to provide reliable, cost-effective alternatives. With over one billion prefilled syringe units supplied and a growing portfolio of ANDA-approved products, Medefil is positioned in the resilient generic injectables market.
Technology Platform
Integrated R&D and state-of-the-art aseptic fill-finish manufacturing platform for prefilled syringes and complex injectable drugs.
Opportunities
Risk Factors
Competitive Landscape
Medefil competes in the generic injectables and prefilled syringe market against large, diversified players like Pfizer (Hospira), Fresenius Kabi, and Hikma Pharmaceuticals. Its differentiation is based on a focused, integrated model emphasizing supply reliability for critical products and expertise in prefilled syringe systems.